Caped Crusader

12/1: 2nd National Stakeholder Meeting. Review of Priorities in the National Vaccine Plan.

In Earth Offenders on November 30, 2008 at 2:14 pm

Event Date:   December 01, 2008 at 8:00am Pacific.

The workshop will focus on topics related to Goal 1 of the update to the National Vaccine Plan (Research and Development), and on draft portions of the update currently being developed by federal agencies with coordination by NVPO. The draft plan will be posted to the project website when it is given to the committee by NVPO (approximately two weeks before the meeting).

This meeting will be AUDIO WEBCAST in real-time. This link will be activated at 8 a.m. PST on December 1, 2008. Registration is not necessary to listen to the webcast–the Beckman
Center was able to provide unlimited access so anyone can join. The link
will be available on the project website at 8:00 a.m. PST on Monday
( The website is being updated right now
to clarify that registration is not needed to listen to the webcast.   

Those listening to the webcast may submit questions or comments during the meeting via email to The committee chair or IOM staff will read the questions/comments to the meeting participants. Due to time constraints questions most relevant to the days discussion (goal 4 of the draft national vaccine plan: research and development) will be addressed first.

The audio files from the meeting and available PowerPoint slides will be posted soon after the meeting. See below for a draft agenda of this meeting.

December 1, 2008: Second national stakeholder meeting, Irvine, CA
December 2, 2008: Closed committee meeting

REGISTRATION for this meeting is open until November 24th.  Registration ensures that we will have materials available for you, but is not required to attend.  Please direct any questions to

For directions to the Beckman Center, click here.

Committee on Review of Priorities in the National Vaccine Plan
Second National Stakeholder Meeting


December 1, 2008

National Academy of Sciences
Beckman Center[1] Huntington Room
100 Academy Way
Irvine, CA

Please note:
Panelists’ titles and affiliations are provided at the end of the agenda.
(*) denotes panelists who will give a formal presentation
(†) panelists who contributed to the draft National Vaccine Plan

8:30 am

Welcome and Committee Introductions

Claire V. Broome
Committee Chair

8:45 – 10:15 am

Panel 1: Encouraging scientific innovation (new vaccines, better vaccines)

Moderator: Milagritos Tapia (IOM committee member)

Philip Dormitzer (Novartis)
Kathryn Edwards (Vanderbilt University)
Harry Greenberg (Stanford University)
Diane Griffin (Johns Hopkins University)
Emil Gotschlich (Rockefeller University)
Ed Mocarski* (MedImmune)
Barbara Mulach† (NIH/NIAID)
Stanley Plotkin* (Sanofi)
Robin Robinson† (HHS/BARDA)
Rebecca Sheets† (NIH/NIAID) (via video)

10:15 – 10:30 pm


10:30 – 11:15 am

Panel 1 continued

11:15 am – 12:30 pm

Panel 2: Financing vaccine research and development

Moderator: Claire V. Broome (IOM committee chair)

Harry B. Greenberg (Stanford University)
Karl D. Handelsman (CMEA Ventures)
David C. Kaslow (Merck)
Leighton Read* (Alloy Ventures)
Jeffrey Ulmer (Novartis)

12:30 – 1:30 pm


1:30 – 3:00 pm

Panel 3: Addressing public needs and priorities

Moderator: Edgar Marcuse (IOM committee member)

Philip R. Dormitzer (Novartis)
Kathryn Edwards (Vanderbilt University)
David C. Kaslow (Merck)
Edward Mocarski (MedImmune)
Stanley A. Plotkin (Sanofi)
Robin Robinson† (HHS/BARDA)

3:00 – 3:15 pm


3:15 – 4:30 pm

Panel 4: Regulatory and other issues in developing and licensing novel processes, new technologies, etc.

Moderator: Arthur Reingold (IOM committee member)

David C. Kaslow (Merck)
Karen Midthun (FDA/CBER)
Leighton Read (Alloy Ventures)
Rebecca Sheets† (NIH/NIAID) (via video)
Jeffrey Ulmer (Novartis)
Karl D. Handelsman (CMEA Ventures )

4:30 – 5:30 pm

Closing dialogue

Question to all stakeholders at the meeting
What criteria would you use to determine what objectives should receive the greatest level of attention in the national vaccine plan?

Final observations about the day’s discussions
All panelists and audience members

5:30 pm



Philip Dormitzer
Senior Director and Senior Project Leader (viral vaccine research)
Novartis Vaccines and Diagnostics

Kathryn Edwards
Sarah Sell Professor of Pediatrics
Director, Division of Pediatric Clinical Research
Vanderbilt University School of Medicine

Harry B. Greenberg
Senior Associate Dean for Research and Training
Stanford University School of Medicine
Professor of Medicine (Gastroenterology & Hepatology) Microbiology and Immunology, and
Staff Physician VA Palo Alto Health Care System

Diane Griffin
Alfred and Jill Sommer Professor and Chair in Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health

Emil Gotschlich
R. Gwin Follis-Chevron Professor
Laboratory of Bacterial Pathogenesis and Immunology
Rockefeller University

Karl D. Handelsman
Managing Director
CMEA Ventures

David C. Kaslow
Vice President, Infectious Diseases and Vaccines Franchise
Merck Research Laboratories

Karen Midthun
Deputy Director, Center for Biologics Evaluation and Research
Food and Drug Administration

Edward S. Mocarski, Jr.*
Distinguished Fellow, MedImmune Vaccines
MedImmune, AstraZeneca
Professor Emeritus Stanford University
Robert W. Woodruff Professor in the Department of Microbiology and Immunology
Emory Vaccine Center, Emory University

Barbara Mulach†
Director, Office of Scientific Coordination and Program Operations
Division of Microbiology and Infectious Diseases (DMID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health

Stanley Plotkin*
Executive Advisor to CEO, Sanofi Pasteur
Emeritus Professor of Pediatrics, University of Pennsylvania

Leighton Read*
General Partner
Alloy Ventures

Robin Robinson†
Director, Biomedical Advanced Research Development Authority
U.S. Department of Health and Human Services

CAPT Rebecca Sheets†
Vaccine Scientific and Regulatory Specialist
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health

Jeffrey Ulmer
Global Head, External Research
Novartis Vaccines and Diagnostics



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: